久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Sunovion Submits NDA for Dasotraline for the Treatment of ADHD Patients americanpharmaceuticalreview.
    September 01, 2017
    Sunovion Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for dasotraline, a novel investigational, dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of children,
PharmaSources Customer Service